C4 Therapeutics (CCCC) has filed to raise $150 million in an IPO of its common stock, according to a S-1 registration statement.
The firm is a preclinical stage biopharma developing cancer and neurodegenerative treatments by creating the ability to destroy disease-causing proteins.
CCCC has created several impressive collaborations, so it appears to be creating a proprietary platform with significant promise.
However, the company is still at a preclinical development stage, so the IPO is likely more suited to long-term hold institutional investors. I’ll watch it from the sidelines.
Company & Technology
Watertown, Massachusetts-based C4 was founded to develop its TORPEDO platform which synthesizes small molecule protein degraders delivered via oral administration for the treatment of blood and other cancers.
Management is headed by president and CEO (as of registration effectiveness date) Mr. Andrew Hirsch, who has been with the firm since September 2020 and is currently a board